CD8A and hepatocellular carcinoma: While challenges such as response durability and identifying optimal combination regimens remain, the targeting of TAMs and CD8+ T cells, particularly through immune checkpoint inhibition, represents a compelling avenue for advancing the treatment landscape of HBV-related HCC.